Edwards Lifesciences ups FY19 adjusted EPS view to $5.50-$5.65 from $5.20-$5.40
Consensus $5.34. For 2019, the company now expects total sales around the top of its previous $4.0B-$4.3B range, consensus $4.23B. "We are very pleased with our strong year-to-date performance. As patients and clinicians increasingly choose TAVR, we remain optimistic about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy. We remain confident that the innovative therapies resulting from our investments will benefit a broader group of patients suffering from structural heart disease and continue to drive strong organic growth," said CEO Michael Mussallem.